Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

NCT01472783 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Recurrent, Epithelial Ovarian Cancer

Interventions

DRUG: Veliparib

Sponsor

Vejle Hospital

Collaborators

[object Object]